The CCC team is heading to Orlando from March 18-20 to attend DIA’s Medical Affairs and Scientific Communications Forum – and we hope we’ll see you there.

This year’s two keynote presentations speak to that very theme. Despite vastly different backgrounds, Jennifer Brea, independent documentary filmmaker, and Deborah Collyar, president of Patients Advocates in Research (PAIR) will lead the event in keynotes that speak to this topic – how to get to the heart of information patients need.

In addition, here are a few sessions our team is looking forward to:

The Future of Medical Affairs – The Voice of the Visionary

There are various ideas, assets, and resources to our industry. This panel interview represents a new concept at MASC. Senior executive industry leaders, founders, and way-makers are being brought together to discuss their vision, why they founded their organizations, answer questions, and demonstrate how they continually move forward. We’ll focus our emphasis on niche markets, organizational design, and necessary business acumen in an ever-changing industry environment, to add as much value as possible. For the manager to director level MI observer, awareness of resources can be unclear. Participants will walk away with invaluable insight to think about what’s coming in the future of our industry, and to be able to apply takeaways for any sized company small, mid-sized, and large Pharma/Biotech.

All Aboard the Globalization Train

The trend towards medical information globalization is clear, but the path and final product can look different for each organization. The results from a survey of several biopharmaceutical companies show us why companies decide to globalize, how they approach this process, and key components to a successful shift towards a global medical information department. We will then see some of these key learnings in action as one company shares their globalization journey.

The Three D’s of RWE

Real-world data (RWD) and real world evidence (RWE) play an increasing role in healthcare decisions. RWD is derived from multiple sources outside typical clinical research settings, including electronic health records (EHRs), claims and billing data, product and disease registries, and data gathered through personal devices and health applications. RWE is the intersection between the structured rigor of a randomized control trial and the clinical exposure a treatment receives once it enters clinical practice as it is derived from analysis of RWD. Medical information departments vary in their understanding and approach to the 3 D’s (definition, decision makers, and dissemination) of RWE. As the US healthcare system continues to seek value for patients, it is increasingly important to have strategies for addressing RWE across the continuum of decision makers (regulators, payers, HCPs and patients).

Podium Pearls 

Medical communications professionals will be presenting their successes, challenges, and “pearls of wisdom” on various topics through podium presentations.

Say hi to the CCC at Booth 207

We’ll be exhibiting throughout the conference, and we’re excited to share the ways organizations are using RightFind Solutions to accelerate the research process and gain scientific insights more quickly.

Attending? Let us know in the comments below!

Author: Keri Mattaliano

Keri Mattaliano is a Director of Corporate Solutions for the RightFind Suite in CCC’s Corporate Business Unit. Keri develops go-to-market strategies, conducts market research and competitive analysis, creates customer personas, and develops product positioning and sales training and tools to drive demand for our products. Keri started with CCC in 2011 and has had roles in customer service, account management and client engagement, including managing the client services team in Cologne, Germany in 2014 & 2015. According to the Master’s degree from Rutgers University that her dad framed, she is a librarian, however, she has never worked in a library.
Don't Miss a Post

Subscribe to the award-winning
Velocity of Content blog